Publications
Selected Key Publications
- Miyake M, Furuya H, Onishi S, Hokutan K, Anai S, Chan O, Shi S, Fujimoto K, Goodison S, Cai W, Rosser CJ. Monoclonal Antibody against CXCL1 (HL2401) as a Novel Agent in Suppressing IL6 Expression and Tumoral Growth. Theranostics. 2019;9(3):853-867. doi: 10.7150/thno.29553. eCollection 2019. PubMed PMID: 30809313; PubMed Central PMCID: PMC6376461.
- Furuya H, Chan OTM, Pagano I, Zhu C, Kim N, Peres R, Hokutan K, Alter S, Rhode P, Rosser CJ. Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model. J Transl Med. 2019 Jan 17;17(1):29. doi: 10.1186/s12967-019-1778-6. PubMed PMID: 30654801; PubMed Central PMCID: PMC6337786.
- Faiena I, Rosser CJ, Chamie K, Furuya H. Diagnostic biomarkers in non-muscle invasive bladder cancer. World J Urol. 2018 Nov 22;. doi: 10.1007/s00345-018-2567-1. [Epub ahead of print] PubMed PMID: 30467596.
- Furuya H, Tamashiro PM, Shimizu Y, Iino K, Peres R, Chen R, Sun Y, Hannun YA, Obeid LM, Kawamori T. Sphingosine Kinase 1 expression in peritoneal macrophages is required for colon carcinogenesis. Carcinogenesis. 2017 Dec 7;38(12):1218-1227. doi: 10.1093/carcin/bgx104. PubMed PMID: 29028945; PubMed Central PMCID: PMC5862304.
- Furuya H, Wada M, Shimizu Y, Yamada PM, Hannun YA, Obeid LM, Kawamori T. Effect of sphingosine kinase 1 inhibition on blood pressure. FASEB J. 2013 Feb;27(2):656-64. doi: 10.1096/fj.12-219014. Epub 2012 Oct 29. PubMed PMID: 23109673; PubMed Central PMCID: PMC3545530.
- Furuya H, Shimizu Y, Kawamori T. Sphingolipids in cancer. Cancer Metastasis Rev. 2011 Dec;30(3-4):567-76. doi: 10.1007/s10555-011-9304-1. Review. PubMed PMID: 22005951.
Contact the Furuya Lab
110 N. George Burns Rd.
Davis, Room 2025
Los Angeles, CA 90048